{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:18:56Z","timestamp":1762917536571},"reference-count":32,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.clinthera.2014.06.024","type":"journal-article","created":{"date-parts":[[2014,7,26]],"date-time":"2014-07-26T13:31:21Z","timestamp":1406381481000},"page":"1217-1225","source":"Crossref","is-referenced-by-count":7,"title":["Evaluation of the Pharmacokinetic Interaction Between Ticagrelor and Venlafaxine, a Cytochrome P-450 2D6 Substrate, in Healthy Subjects"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01350921","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Renli","family":"Teng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjana","family":"Kujacic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.06.024_bib1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1755-5922.2009.00096.x","article-title":"Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist","volume":"27","author":"Husted","year":"2009","journal-title":"Cardiovas Ther"},{"key":"10.1016\/j.clinthera.2014.06.024_bib2","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.06.024_bib3","unstructured":"Brilinta prescribing information. http:\/\/www1.astrazeneca-us.com\/pi\/brilinta.pdf#page=1. Accessed May 21, 2014."},{"key":"10.1016\/j.clinthera.2014.06.024_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2125.2010.03669.x","article-title":"Pharmacokinetics pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers","volume":"70","author":"Butler","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.024_bib5","first-page":"e426","article-title":"AZD6140, the first reversible oral platelet P2Y12 receptor antagonist, has linear pharmacokinetics and provides near complete inhibition of platelet aggregation, with reversibility of effect in healthy subjects","volume":"15","author":"Teng","year":"2010","journal-title":"Can J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.024_bib6","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00228-009-0778-5","article-title":"Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects","volume":"66","author":"Teng","year":"2010","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.024_bib7","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1124\/dmd.110.032250","article-title":"Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects","volume":"38","author":"Teng","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2014.06.024_bib8","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurheartj\/ehi754","article-title":"Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin","volume":"27","author":"Husted","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2014.06.024_bib9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1124\/dmd.110.037143","article-title":"In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction and differential kinetics","volume":"39","author":"Zhou","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2014.06.024_bib10","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehr236","volume":"32","author":"Hamm","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2014.06.024_bib11","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jacc.2012.06.004","volume":"60","author":"Jneid","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2014.06.024_bib12","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00228-012-1369-4","article-title":"Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers","volume":"69","author":"Teng","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.024_bib13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.clinthera.2013.06.003","article-title":"The effect of ticagrelor on the metabolism of midazolam in healthy volunteers","volume":"35","author":"Teng","year":"2013","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.06.024_bib14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/21556660.2013.785413","article-title":"Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers","volume":"2","author":"Teng","year":"2013","journal-title":"J Drug Asses"},{"key":"10.1016\/j.clinthera.2014.06.024_bib15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.DMPK-11-RV-121","article-title":"Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance","volume":"27","author":"Teh","year":"2012","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clinthera.2014.06.024_bib16","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1001\/archinte.160.9.1354","article-title":"Depression and 1-year prognosis in unstable angina","volume":"160","author":"Lesperance","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2014.06.024_bib17","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.amjcard.2005.06.052","article-title":"Effect of depression on five-year mortality after an acute coronary syndrome","volume":"96","author":"Grace","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2014.06.024_bib18","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1182\/blood-2011-09-336933","article-title":"Transporters in human platelets: physiologic function and impact for pharmacotherapy","volume":"119","author":"Jedlitschky","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.06.024_bib19","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.thromres.2013.02.007","article-title":"Selective serotonin reuptake inhibitors reduce P2Y12 receptor-mediated amplification of platelet aggregation","volume":"131","author":"Tseng","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.clinthera.2014.06.024_bib20","doi-asserted-by":"crossref","first-page":"e000544","DOI":"10.1136\/bmjopen-2011-000544","article-title":"Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants","volume":"2","author":"Castro","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.clinthera.2014.06.024_bib21","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/ajg.2009.128","article-title":"Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding","volume":"104","author":"Targownik","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2014.06.024_bib22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2125.1996.tb00173.x","article-title":"Venlafaxine oxidation in vitro is catalysed by CYP2D6","volume":"41","author":"Otton","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.024_bib23","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","article-title":"O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants","volume":"20","author":"Fogelman","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2014.06.024_bib24","unstructured":"Venlafaxine prescribing information. http:\/\/www.drugs.com\/pro\/venlafaxine.html. Accessed May 16, 2014."},{"key":"10.1016\/j.clinthera.2014.06.024_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/11594710-000000000-00000","article-title":"Clinically significant drug interactions with newer antidepressants","volume":"26","author":"Spina","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2014.06.024_bib26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/j.1552-4604.1995.tb04081.x","article-title":"The pharmacokinetics of venlafaxine when given in a twice-daily regimen","volume":"35","author":"Troy","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2014.06.024_bib27","doi-asserted-by":"crossref","first-page":"478","DOI":"10.5414\/CP202017","article-title":"Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers","volume":"52","author":"Teng","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2014.06.024_bib28","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/j.jchromb.2010.06.018","article-title":"Determination of ticagrelor and two metabolites in plasma samples by liquid chromatography and mass spectrometry","volume":"878","author":"Sill\u00e9n","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clinthera.2014.06.024_bib29","unstructured":"Columbia University Medical Center (CUMC). Columbia\u2013Suicide Severity Rating Scale (C-SSRS). http:\/\/www.cssrs.columbia.edu\/index.html. Accessed March 20, 2014."},{"key":"10.1016\/j.clinthera.2014.06.024_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2014.06.024_bib31","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1592\/phco.27.6.874","article-title":"Pharmacogenetics of beta-blockers","volume":"27","author":"Shin","year":"2007","journal-title":"Pharmacotherapy"},{"issue":"3 Suppl. 2","key":"10.1016\/j.clinthera.2014.06.024_bib32","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.1097\/00004714-199606002-00011","article-title":"The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database","volume":"16","author":"Rudolph","year":"1996","journal-title":"J Clin Psychopharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814003889?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814003889?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T09:54:43Z","timestamp":1538387683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814003889"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0149291814003889"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.024","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}